Dr. Jacob Becraft, CEO of Strand Therapeutics and a member of the BIO board, told the House Select Committee on China that China’s biotech ecosystem has accelerated clinical trial timelines—reducing ideation‑to‑first‑in‑human to roughly one year versus two‑to‑three years in the U.S. He urged policy changes to preserve U.S. competitiveness and domestic clinical data generation. Becraft outlined how decentralization and expedited trial pathways have increased China’s share of global licensing deals and warned of national‑security and supply‑chain implications if clinical leadership migrates overseas. His testimony cited committee figures showing Chinese‑origin molecules now feature in a substantially larger share of large pharma deals.